The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | The evolution of treatment for elderly patients with CLL
Parag Jasani, MBBS, MRCP, FRCPath, FRCP, University College London Hospital, London, UK, explains how the treatment of elderly patients with chronic lymphocytic leukemia (CLL) has changed, with the introduction of novel agents that are more tolerable than chemoimmunotherapy. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
